Enterococcus species are bacteria that normally live in the human gut without causing harm, but they rank among the most common causes of hospital-acquired infections when they reach sites like the bloodstream, urinary tract, or heart valves. The genus includes over 50 species, though two dominate human disease: Enterococcus faecalis and Enterococcus faecium. What makes these organisms particularly troublesome is their ability to resist a wide range of antibiotics, a trait that has intensified over the past three decades and turned routine hospital infections into serious treatment challenges.
How Enterococci Go From Harmless to Dangerous
The name “Enterococcus” literally points to the gut: these bacteria were first isolated from human feces in the early 1900s and thrive as commensals in the gastrointestinal tracts of mammals, birds, reptiles, and even insects.1PubMed Central. Enterococci and Their Interactions with the Intestinal Microbiome In a healthy person, they make up a small fraction of the gut’s microbial community and are kept in check by the surrounding ecosystem of other bacteria. The trouble starts when that ecosystem is disrupted, most often by antibiotics. Broad-spectrum antibiotic treatment wipes out competing gut microbes, giving resistant enterococci the space to multiply unchecked and densely colonize the intestine. From there, the bacteria can spread to other body sites through breaks in the gut lining, surgical wounds, or indwelling medical devices like urinary catheters and central venous lines.
This sequence explains why enterococcal infections are overwhelmingly hospital-acquired. The patients most at risk are those receiving prolonged courses of antibiotics, spending extended time in intensive care units, or undergoing invasive procedures. A prospective study in a surgical ICU found that longer ICU stays and treatment with certain broad-spectrum antibiotics were significantly associated with acquiring vancomycin-resistant enterococci (VRE).2PubMed Central. Hospital acquired vancomycin resistant enterococci in surgical intensive care patients – a prospective longitudinal study Separate research on critically ill patients identified additional risk factors: prior hospitalization, chronic kidney failure, chronic heart failure, cancer, insulin-dependent diabetes, and having other VRE-positive patients in nearby beds.3PubMed. Risk factors for enterococcal infection and colonization by vancomycin-resistant enterococci in critically ill patients The common thread is debilitation combined with a medical environment that favors transmission.
The Two Species That Matter Most
E. faecalis and E. faecium account for the vast majority of human enterococcal infections, but they behave quite differently. E. faecalis is by far the more common of the two in clinical isolates and tends to infect patients who are less severely ill at baseline. E. faecium, on the other hand, disproportionately strikes patients who are already debilitated: those with cancer, neutropenia, kidney dysfunction, or those on corticosteroids and prior antibiotic courses. In one comparative study, mortality from E. faecium bloodstream infections was dramatically higher than from E. faecalis bloodstream infections, at roughly 50% versus 11%.4Clinical Infectious Diseases. Enterococcus faecium and Enterococcus faecalis Bacteremia: Acquisition and Outcome
Part of this mortality gap reflects the patient populations each species targets, but the biology also differs. E. faecium carries greater intrinsic resistance to many antibiotics, making it harder to treat. Research on vancomycin-resistant strains found that VR E. faecalis bloodstream infections had more than two-fold lower in-hospital mortality compared to VR E. faecium, possibly because beta-lactam antibiotics like ampicillin still work against most E. faecalis strains but not against E. faecium.5PubMed Central. Comparison of the clinical characteristics and outcomes associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant E. faecium bacteremia Meanwhile, E. faecalis excels at forming biofilms, the sticky bacterial communities that coat medical devices. In laboratory testing, all E. faecalis isolates formed biofilms, compared with only about 42% of E. faecium isolates, and the E. faecalis strains from catheter-related bloodstream infections produced significantly more biofilm than other strains.6PubMed. Correlation between enterococcal biofilm formation in vitro and medical-device-related infection potential in vivo So each species has its own strengths as a pathogen: E. faecalis clings to devices, while E. faecium resists more drugs.
What Enterococcal Infections Look Like
Enterococci cause a range of infections, and symptoms depend entirely on where the bacteria end up. The major clinical presentations include urinary tract infections, bloodstream infections (bacteremia), endocarditis, intra-abdominal infections, wound infections, and neonatal sepsis.7PubMed. Clinical manifestations of enterococcal infection
Urinary Tract Infections
UTIs are among the most frequent enterococcal infections. Enterococci have become a leading cause of healthcare-associated urinary infections, often linked to catheter use.8PubMed Central. Enterococcal Urinary Tract Infections: A Review of the Pathogenicity, Epidemiology, and Treatment Symptoms mirror those of any UTI: burning during urination, frequent urges to urinate, cloudy or foul-smelling urine, and sometimes lower abdominal pain. In catheterized patients, fever may be the only sign. What sets enterococcal UTIs apart is their stubbornness. Research has shown that E. faecalis can invade the cells lining the bladder wall, essentially hiding inside the tissue in a way that may contribute to chronic or recurrent infections.9PLOS ONE. Enterococcus faecalis Subverts and Invades the Host Urothelium in Patients with Chronic Urinary Tract Infection
Endocarditis
Enterococcal endocarditis, an infection of the heart valves, is less common than UTIs but far more dangerous. E. faecalis is the species most commonly implicated. The typical presentation is a subacute illness with persistent fever, fatigue, and vague aches that can be easily mistaken for other conditions.10PubMed. Enterococcus faecalis infective endocarditis: focus on clinical aspects Because the symptoms are nonspecific, diagnosis is often delayed. Complications can be severe: one case report described a patient whose E. faecalis endocarditis affected all four heart valves and led to an epidural abscess, spinal disc infection, and splenic infarction.11PubMed Central. Enterococcus faecalis Endocarditis of All Four Native Valves: A Case Report Though that case was extreme, it illustrates the bacteria’s potential to seed distant organs through the bloodstream.
Intra-Abdominal and Wound Infections
Enterococci regularly show up in abdominal infections, particularly after surgery. In a study of 200 patients with complicated intra-abdominal sepsis, enterococci were isolated in about 21% overall, but the rate jumped to 50% in patients with postoperative peritonitis.12PubMed. Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis Surgical revision specifically increases the likelihood of finding enterococci in wound infections, with one study reporting that operative revision roughly tripled the odds of enterococcal presence in superficial surgical site infections.13PubMed. Surgical Revision Promotes Presence of Enterococcus spp. in Abdominal Superficial Surgical Site Infections These wound infections are often polymicrobial, meaning enterococci are sharing space with other bacteria, which complicates treatment decisions. Beyond surgical wounds, enterococci are also found in burns, pressure ulcers, and diabetic foot infections.7PubMed. Clinical manifestations of enterococcal infection
Why Antibiotic Resistance Is the Central Problem
Enterococci are inherently tough organisms. They tolerate bile salts, high salt concentrations, and a wide pH range, which is partly why they survive so well in the gut and in hospital environments. But what elevates them from nuisance to serious threat is their resistance to antibiotics. These bacteria have developed resistance to virtually every class of antibiotic used in clinical practice, using strategies that include altering the drug’s target, producing enzymes that inactivate the drug, and pumping drugs out of the cell before they can work.14PubMed Central. Mechanisms of antibiotic resistance in enterococci
The most clinically significant form of resistance is to vancomycin, a glycopeptide antibiotic long considered a drug of last resort for serious gram-positive infections. VRE strains carry gene clusters, most commonly designated vanA and vanB, that alter the bacterial cell wall target so vancomycin can no longer bind effectively.15PubMed Central. Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin The resistance is controlled by a sensing system: a protein on the bacterial surface detects vancomycin and activates the genes that rebuild the cell wall in a form the drug cannot recognize.16PubMed Central. Regulation of Resistance in Vancomycin-Resistant Enterococci: The VanRS Two-Component System It is a remarkably efficient defense. And because enterococci can transfer resistance genes to other bacteria, VRE is not just a problem in itself but a potential source of resistance for other dangerous organisms.
In U.S. hospitals, widespread antibiotic use has fueled the transmission of multidrug-resistant enterococci, and the cycle is self-reinforcing: antibiotics create the conditions for resistant strains to dominate, and the presence of resistant strains demands different (and often broader) antibiotics.1PubMed Central. Enterococci and Their Interactions with the Intestinal Microbiome
Treatment Options and Their Limitations
For infections caused by E. faecalis that remain susceptible to standard antibiotics, ampicillin is the backbone of treatment, often combined with a second agent for synergy. Endocarditis caused by E. faecalis, for instance, has traditionally been treated with ampicillin plus an aminoglycoside like gentamicin, though high rates of aminoglycoside resistance have pushed clinicians toward newer dual beta-lactam combinations. Research on ampicillin plus ceftobiprole found strong bactericidal activity against enterococcal strains, with both drugs achieving adequate concentrations in the blood of patients treated for endocarditis or bloodstream infections.17Nature. Evaluation of ampicillin plus ceftobiprole combination therapy in treating Enterococcus faecalis infective endocarditis and bloodstream infection
VRE infections, predominantly caused by E. faecium, present a much narrower set of treatment options. The two agents used most often are linezolid and daptomycin, and deciding between them is not straightforward. A meta-analysis pooling data from ten studies found that patients treated with daptomycin had significantly higher 30-day mortality and infection-related mortality compared with those treated with linezolid for VRE bloodstream infections.18PubMed Central. Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia A separate single-center study reinforced this, finding that clinical failure was significantly more common with standard-dose daptomycin than with linezolid.19PubMed Central. Comparison of linezolid and daptomycin for the treatment of vancomycin-resistant enterococcal bacteremia
However, a more recent meta-analysis came to a somewhat different conclusion, finding that when higher doses of daptomycin were used, clinical and microbiological outcomes were comparable to linezolid, with daptomycin showing a lower rate of thrombocytopenia (a drop in blood platelets that is a known side effect of linezolid).20Journal of Global Antimicrobial Resistance. Efficacy and safety of daptomycin versus linezolid treatment in patients with vancomycin-resistant enterococcal bacteraemia: An updated systematic review and meta-analysis The takeaway from this evidence is that dosing matters enormously for daptomycin: standard doses appear to underperform, while higher doses may close the gap with linezolid. This makes the choice between the two drugs a judgment call based on the severity of infection, the patient’s platelet count, and whether higher daptomycin dosing is feasible.
Phage Therapy and Future Directions
With the pipeline for new antibiotics against multidrug-resistant enterococci running thin, researchers have turned increasing attention to bacteriophages, viruses that specifically infect and kill bacteria. Phage therapy against E. faecium has shown promising results in laboratory models and in a small number of compassionate-use clinical cases, with phages demonstrating the ability to disrupt biofilms and work synergistically with antibiotics.21PubMed Central. Bacteriophage Therapy as a Promising Alternative for Antibiotic-Resistant Enterococcus faecium: Advances and Challenges Phages offer an appealing property: their narrow host range means they target the pathogen without collateral damage to the rest of the gut microbiome, which is the very damage that antibiotics cause and that allows enterococci to take over in the first place. Phage therapy remains experimental and faces practical hurdles around manufacturing, regulation, and matching the right phage to the right bacterial strain, but it represents one of the more active areas of research for a problem that badly needs new solutions.
How Enterococcal Infections Are Identified
Diagnosing an enterococcal infection starts with standard microbiology: a clinical sample such as blood, urine, or wound fluid is cultured, and the bacteria that grow are identified. Modern clinical laboratories increasingly use MALDI-TOF mass spectrometry to identify bacterial species within minutes from a colony, replacing older biochemical tests that could take a day or more.22PubMed. From days to hours: Can MALDI-TOF MS system replace both conventional and molecular typing methods with new cut off level for Vancomycin Resistant Enterococcus faecium Once the organism is identified as an enterococcus, the critical next step is determining whether it is resistant to vancomycin. This can be done through traditional susceptibility testing on growth media, or faster by using targeted molecular methods that detect vanA and vanB resistance genes directly from the isolate.23Journal of Antimicrobial Chemotherapy. Complementary use of MALDI-TOF MS and real-time PCR–melt curve analysis for rapid identification of methicillin-resistant staphylococci and VRE Speed matters here: the sooner clinicians know they are dealing with VRE, the sooner they can switch to an effective antibiotic and implement isolation precautions to prevent spread.
Preventing Spread in Hospitals
Because enterococci are hardy enough to survive on surfaces for days, environmental contamination plays a real role in hospital transmission. A randomized controlled trial across Australian hospitals tested a multimodal cleaning bundle that focused on product selection, cleaning technique, staff training, auditing with feedback, and communication. The intervention increased the proportion of high-touch surfaces cleaned properly and reduced VRE infections from 0.35 to 0.22 per 10,000 occupied bed-days, a roughly 37% reduction.24The Lancet Infectious Diseases. Effectiveness of a multimodal environmental cleaning bundle and health care-associated infections in Australian hospitals (REACH): a randomised controlled trial Another investigation in a medical ICU confirmed that decreasing environmental contamination helped control VRE spread.25Clinical Infectious Diseases. Reduction in Acquisition of Vancomycin-Resistant Enterococcus after Enforcement of Routine Environmental Cleaning Measures
Hand hygiene remains the single most important measure. Enterococci are readily transferred on healthcare workers’ hands between patients, and the combination of thorough surface cleaning with consistent hand hygiene produces better results than either measure alone. Hospitals dealing with VRE outbreaks also typically isolate colonized or infected patients in private rooms, use dedicated equipment, and screen contacts through rectal swabs.
Enterococcal Infections in Newborns and Children
Enterococcal bloodstream infections skew heavily toward the very youngest patients. In a pediatric study, the median age of children with enterococcal bacteremia was less than one year, with 42% of cases occurring in neonates under one month old. The vast majority had significant underlying conditions, especially prematurity, cardiac disease, and gastrointestinal disorders. Nearly 88% had received prior broad-spectrum antibiotics, and about 84% acquired the infection in the hospital. Intravascular devices were the most commonly identified source of the bacteremia.26Pediatrics & Neonatology. Enterococcal bacteremia in children: Clinical characteristics and antimicrobial resistance In neonatal intensive care units, the risk profile mirrors that of adult ICUs: prolonged hospitalization, invasive lines, and antibiotic exposure all converge to create an environment where enterococci thrive.
Enterococci Outside the Hospital
Enterococci have a second life as environmental organisms. Because they are shed in feces, they end up in waterways, soil, and food products. Public health agencies worldwide use enterococci as indicator organisms to monitor fecal contamination in recreational water.27PubMed Central. Persistence and differential survival of fecal indicator bacteria in subtropical waters and sediments When a beach gets a high enterococcus count, swimming advisories follow. But interpreting those counts is not as simple as it sounds. Research has shown that enterococci can survive and even grow in association with aquatic plankton and decaying plant material, meaning elevated counts do not always reflect recent fecal contamination.28PubMed Central. Persistence and growth of the fecal indicator bacteria enterococci in detritus and natural estuarine plankton communities This creates headaches for regulators trying to determine whether a beach is genuinely unsafe or just has high background enterococcal levels from environmental sources.
There has also been concern about antibiotic-resistant enterococci moving between livestock and humans through the food chain. A large genomic surveillance study in the United Kingdom, however, found that the E. faecium strains infecting hospital patients were largely distinct from those found in livestock, with limited sharing of resistance genes between the two populations.29PubMed Central. Genomic Surveillance of Enterococcus faecium Reveals Limited Sharing of Strains and Resistance Genes between Livestock and Humans in the United Kingdom That finding offers some reassurance, though it comes from a single national setting and may not hold everywhere. The broader question of how agricultural antibiotic use contributes to resistance in human enterococcal infections remains an active area of investigation, and the answer likely varies by country depending on farming practices and antibiotic stewardship policies.